Cost-effectiveness analysis of inhaled zanamivir in the treatment of influenza A and B in high-risk patients

Objective: To evaluate the cost effectiveness of zanamivir 10mg twice daily for 5 days in the treatment of influenza in high-risk patients. Design: Bootstrap cost-effectiveness analysis incorporating within-trial an alysis of pooled patient-level cost and effect data. Setting: UK unit costs and utilities applied to high-risk patients drawn fr om 6 multinational clinical trials. Patients: A total of 154 zanamivir and 167 placebo high-risk patients were included in the analysis. Main outcome measures: Cost per day of normal activities: cost per symptom- free day; cost per complication averted: cost per quality-adjusted life-yea r (QALY). Results: The mean benefit was estimated to be 2.5 days [95% confidence inte rval (CI): 0.68 to 4.27] of normal activities gained; 2.0 (95% CI: 0.56 to 3.51) symptom-free days; and a 9% reduction in complications (95% CI: 0 to 18%). Excluding the effect of rare hospitalisation costs, the cost (1999 va lues) of gaining a day of normal activities was pound9.50 (95% CI: pound5 t o pound 39); cost per symptom-fret day was pound 11.56 (95% CI: pound6 to p ound 43); cost per complication averted was pound 262 (95% CI: pound 90 to pound 1574). Influenza was estimated to reduce utility by 0.883 per day. de monstrating the debilitating effect of the disease. Extrapolating a day of normal activities to a standard utility measure resulted in a cost per QALY of pound 3900 excluding inpatient costs (pound 7490 including inpatient co sts). Cost-effectiveness acceptability curves demonstrated 90% certainty th at zanamivir would be cost effective at pound 8000 per QALY. Conclusions: Significant health benefits can be obtained with zanamivir tre atment in high-risk patients. The cost pet QALY for zanamivir in these pati ents compares well with that of other commonly used pharmacological interve ntions.